SCHEMBL29790809

SCHEMBL29790809

COc1cc2ncn3ncnc3c2cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
KDR P35968 7/20 0.38
FLT1 P17948 2/20 0.38
EGFR P00533 6/20 0.37
ACVR1 Q04771 4/20 0.35
KIT P10721 2/20 0.35
FGFR1 P11362 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
RET P07949 2/20 0.34
KIF5B P33176 2/20 0.34
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
ABL1 P00519 1/20 0.34
HCK P08631 1/20 0.34
SRC P12931 1/20 0.34
PIK3CB P42338 1/20 0.34
MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475899 0.74 ADORA2A (0.46)
SCHEMBL29790789 0.74 EGFR (0.42) TRPA1KDM4EALDH1A1MAPK1EGFR
SCHEMBL14842794 0.69 TRPA1 (0.51) TRPA1KDRFLT1EGFRKIT
SCHEMBL29790801 0.69 HTR1A (0.43) KDM4EEGFR
SCHEMBL24837347 0.68 PDGFRA (0.55) KDREGFR
SCHEMBL24008957 0.68 ENPP1 (0.63) TRPA1KDRFLT1EGFRKIT
SCHEMBL24393287 0.66 EGFR (0.58) KDM4EALDH1A1MAPK1KDRFLT1
SCHEMBL24392135 0.66 TRPA1 (0.48) TRPA1KDRFLT1EGFRKIT
SCHEMBL24009147 0.65 PDGFRA (0.44) TRPA1KDREGFRACVR1ABL1
SCHEMBL30277469 0.65 MAOB (0.50) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060357-B2 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use MERCK SHARP & DOHME LLC (US) 2024-08-13 US disclosed
US-20220220117-A1 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2022-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220117-A1 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE ADORA2A, ADORA2B, ADORA3 TRPA1 552/4885KDM4E 3535/4885ALDH1A1 815/4885
US-12060357-B2 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use ADORA2A, ADORA2B, ADORA3 TRPA1 552/4885KDM4E 3535/4885ALDH1A1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.